ArticleNeurology2016
Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly.
Open access · bronzeAbstract read
In one paragraph
Article in Neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 1 pooled it
11.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.
- Mental health dished up-the use of iPSC models in neuropsychiatric research.Journal of neural transmission (Vienna, Austria : 1996) · 2020Pooled it
- Evaluation of tau deposition usingAlzheimer's research & therapy · 2022Trial
- Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Late-life emergence of neuropsychiatric symptoms and risk of cognitive impairment in cognitively unimpaired individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- "Advances in biomarker discovery and diagnostics for alzheimer's disease".Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- New Research on Biomarkers in Alzheimer's Continuum.Reviews on recent clinical trials · 2025Review
- Cerebrospinal fluid tau and disease progression in early Parkinson's disease: an 8-year longitudinal study.Journal of neurology · 2024Article
- Alcohol Use Disorder and Dementia: A Review.Alcohol research : current reviews · 2024Review
- A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles.Brain communications · 2024Review
- Eye movement patterns during viewing face images with neutral expressions in patients with early-stage Alzheimer's disease and amnestic mild cognitive impairment.Brain and behavior · 2023Article
- The Sensitivity of Tau Tracers for the Discrimination of Alzheimer's Disease Patients and Healthy Controls by PET.Biomolecules · 2023Review
- PET molecular imaging for pathophysiological visualization in Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2023Review
- APOE ε4 genotype, amyloid-β, and sex interact to predict tau in regions of high APOE mRNA expression.Science translational medicine · 2022Article
- CSF phosphorylated tau as an indicator of subsequent tau accumulation.Neurobiology of aging · 2022Article
- Tracers progress for positron emission tomography imaging of glial-related disease.Journal of biomedical research · 2022Article
- Site-Specific Cerebrospinal Fluid Tau Hyperphosphorylation in Response to Alzheimer's Disease Brain Pathology: Not All Tau Phospho-Sites are Hyperphosphorylated.Journal of Alzheimer's disease : JAD · 2022Article
- APOEε4 potentiates the relationship between amyloid-β and tau pathologies.Molecular psychiatry · 2021Article
- Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia.European journal of nuclear medicine and molecular imaging · 2021Article
- Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts.European journal of nuclear medicine and molecular imaging · 2021Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 2 countries.
Jasmeer P ChhatwalFrom Harvard Medical School (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., C.S., B.T.H., R.A.S., K.A.J.); Massachusetts General Hospital (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., J.D., M.L., A.D.R., B.T.H., R.A.S., K.A.J.), Boston; Martinos Center for Biomedical Imaging (J.P.C., A.P.S., M.L., R.A.S., K.A.J.), Charlestown; Brigham and Women's Hospital (G.A.M., B.B., C.S., R.A.S., K.A.J.), Boston; Biogen (B.B.), Cambridge, MA; Lariboisiere Hospital Memory Center (J.D.), APHP, University Paris 7 Denis Diderot, France; and Harvard NeuroDiscovery Center (C.S.), Boston, MA.
Aaron P SchultzFrom Harvard Medical School (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., C.S., B.T.H., R.A.S., K.A.J.); Massachusetts General Hospital (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., J.D., M.L., A.D.R., B.T.H., R.A.S., K.A.J.), Boston; Martinos Center for Biomedical Imaging (J.P.C., A.P.S., M.L., R.A.S., K.A.J.), Charlestown; Brigham and Women's Hospital (G.A.M., B.B., C.S., R.A.S., K.A.J.), Boston; Biogen (B.B.), Cambridge, MA; Lariboisiere Hospital Memory Center (J.D.), APHP, University Paris 7 Denis Diderot, France; and Harvard NeuroDiscovery Center (C.S.), Boston, MA.
Gad A MarshallFrom Harvard Medical School (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., C.S., B.T.H., R.A.S., K.A.J.); Massachusetts General Hospital (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., J.D., M.L., A.D.R., B.T.H., R.A.S., K.A.J.), Boston; Martinos Center for Biomedical Imaging (J.P.C., A.P.S., M.L., R.A.S., K.A.J.), Charlestown; Brigham and Women's Hospital (G.A.M., B.B., C.S., R.A.S., K.A.J.), Boston; Biogen (B.B.), Cambridge, MA; Lariboisiere Hospital Memory Center (J.D.), APHP, University Paris 7 Denis Diderot, France; and Harvard NeuroDiscovery Center (C.S.), Boston, MA.
Brendon BootFrom Harvard Medical School (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., C.S., B.T.H., R.A.S., K.A.J.); Massachusetts General Hospital (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., J.D., M.L., A.D.R., B.T.H., R.A.S., K.A.J.), Boston; Martinos Center for Biomedical Imaging (J.P.C., A.P.S., M.L., R.A.S., K.A.J.), Charlestown; Brigham and Women's Hospital (G.A.M., B.B., C.S., R.A.S., K.A.J.), Boston; Biogen (B.B.), Cambridge, MA; Lariboisiere Hospital Memory Center (J.D.), APHP, University Paris 7 Denis Diderot, France; and Harvard NeuroDiscovery Center (C.S.), Boston, MA.
Teresa Gomez-IslaFrom Harvard Medical School (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., C.S., B.T.H., R.A.S., K.A.J.); Massachusetts General Hospital (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., J.D., M.L., A.D.R., B.T.H., R.A.S., K.A.J.), Boston; Martinos Center for Biomedical Imaging (J.P.C., A.P.S., M.L., R.A.S., K.A.J.), Charlestown; Brigham and Women's Hospital (G.A.M., B.B., C.S., R.A.S., K.A.J.), Boston; Biogen (B.B.), Cambridge, MA; Lariboisiere Hospital Memory Center (J.D.), APHP, University Paris 7 Denis Diderot, France; and Harvard NeuroDiscovery Center (C.S.), Boston, MA.
Julien DumurgierFrom Harvard Medical School (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., C.S., B.T.H., R.A.S., K.A.J.); Massachusetts General Hospital (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., J.D., M.L., A.D.R., B.T.H., R.A.S., K.A.J.), Boston; Martinos Center for Biomedical Imaging (J.P.C., A.P.S., M.L., R.A.S., K.A.J.), Charlestown; Brigham and Women's Hospital (G.A.M., B.B., C.S., R.A.S., K.A.J.), Boston; Biogen (B.B.), Cambridge, MA; Lariboisiere Hospital Memory Center (J.D.), APHP, University Paris 7 Denis Diderot, France; and Harvard NeuroDiscovery Center (C.S.), Boston, MA.
Molly LaPointFrom Harvard Medical School (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., C.S., B.T.H., R.A.S., K.A.J.); Massachusetts General Hospital (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., J.D., M.L., A.D.R., B.T.H., R.A.S., K.A.J.), Boston; Martinos Center for Biomedical Imaging (J.P.C., A.P.S., M.L., R.A.S., K.A.J.), Charlestown; Brigham and Women's Hospital (G.A.M., B.B., C.S., R.A.S., K.A.J.), Boston; Biogen (B.B.), Cambridge, MA; Lariboisiere Hospital Memory Center (J.D.), APHP, University Paris 7 Denis Diderot, France; and Harvard NeuroDiscovery Center (C.S.), Boston, MA.
Clemens ScherzerFrom Harvard Medical School (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., C.S., B.T.H., R.A.S., K.A.J.); Massachusetts General Hospital (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., J.D., M.L., A.D.R., B.T.H., R.A.S., K.A.J.), Boston; Martinos Center for Biomedical Imaging (J.P.C., A.P.S., M.L., R.A.S., K.A.J.), Charlestown; Brigham and Women's Hospital (G.A.M., B.B., C.S., R.A.S., K.A.J.), Boston; Biogen (B.B.), Cambridge, MA; Lariboisiere Hospital Memory Center (J.D.), APHP, University Paris 7 Denis Diderot, France; and Harvard NeuroDiscovery Center (C.S.), Boston, MA.
Allyson D RoeFrom Harvard Medical School (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., C.S., B.T.H., R.A.S., K.A.J.); Massachusetts General Hospital (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., J.D., M.L., A.D.R., B.T.H., R.A.S., K.A.J.), Boston; Martinos Center for Biomedical Imaging (J.P.C., A.P.S., M.L., R.A.S., K.A.J.), Charlestown; Brigham and Women's Hospital (G.A.M., B.B., C.S., R.A.S., K.A.J.), Boston; Biogen (B.B.), Cambridge, MA; Lariboisiere Hospital Memory Center (J.D.), APHP, University Paris 7 Denis Diderot, France; and Harvard NeuroDiscovery Center (C.S.), Boston, MA.
Bradley T HymanFrom Harvard Medical School (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., C.S., B.T.H., R.A.S., K.A.J.); Massachusetts General Hospital (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., J.D., M.L., A.D.R., B.T.H., R.A.S., K.A.J.), Boston; Martinos Center for Biomedical Imaging (J.P.C., A.P.S., M.L., R.A.S., K.A.J.), Charlestown; Brigham and Women's Hospital (G.A.M., B.B., C.S., R.A.S., K.A.J.), Boston; Biogen (B.B.), Cambridge, MA; Lariboisiere Hospital Memory Center (J.D.), APHP, University Paris 7 Denis Diderot, France; and Harvard NeuroDiscovery Center (C.S.), Boston, MA.
Reisa A SperlingFrom Harvard Medical School (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., C.S., B.T.H., R.A.S., K.A.J.); Massachusetts General Hospital (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., J.D., M.L., A.D.R., B.T.H., R.A.S., K.A.J.), Boston; Martinos Center for Biomedical Imaging (J.P.C., A.P.S., M.L., R.A.S., K.A.J.), Charlestown; Brigham and Women's Hospital (G.A.M., B.B., C.S., R.A.S., K.A.J.), Boston; Biogen (B.B.), Cambridge, MA; Lariboisiere Hospital Memory Center (J.D.), APHP, University Paris 7 Denis Diderot, France; and Harvard NeuroDiscovery Center (C.S.), Boston, MA.
Keith A JohnsonFrom Harvard Medical School (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., C.S., B.T.H., R.A.S., K.A.J.); Massachusetts General Hospital (J.P.C., A.P.S., G.A.M., B.B., T.G.-I., J.D., M.L., A.D.R., B.T.H., R.A.S., K.A.J.), Boston; Martinos Center for Biomedical Imaging (J.P.C., A.P.S., M.L., R.A.S., K.A.J.), Charlestown; Brigham and Women's Hospital (G.A.M., B.B., C.S., R.A.S., K.A.J.), Boston; Biogen (B.B.), Cambridge, MA; Lariboisiere Hospital Memory Center (J.D.), APHP, University Paris 7 Denis Diderot, France; and Harvard NeuroDiscovery Center (C.S.), Boston, MA. kajohnson@pet.mgh.harvard.edu.
Hôpital Lariboisière · FRBiogen (United States) · USBrigham and Women's Hospital · USAssistance Publique – Hôpitaux de Paris · FRAthinoula A. Martinos Center for Biomedical Imaging · USDélégation Paris 7 · FRHarvard University · USUniversité Paris Cité · FR
Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MHarvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2MRECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6MVascular factors, physical activity, and inflammation as modulators of neurodegenerative and cognitive trajectories (Project 2)P01AG036694 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Frances Buckley, Keith A. Johnson · 2010 to 2026
$50.2MHarvard Clinical and Translational Science Center (UL1)UL1TR000170 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2012 to 2013
$31.4MDisentangling the contribution of tau to aging and ADR01AG046396 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI JOHNSON, KEITH A. · 2014 to 2018
$4.0MBiomarkers for early intervention in Parkinson diseaseU01NS082157 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHERZER, CLEMENS R · 2012 to 2016
$2.5MMentoring Imaging Research in Early ADK24AG035007 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI SPERLING, REISA A. · 2010 to 2020
$1.4MAge and genetic influence on fcMRI networks in autosomal dominant and sporadic ADK23AG049087 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI CHHATWAL, JASMEER P · 2015 to 2019
$931kNCATS NIH HHS UL1 TR000170NCATS NIH HHS UL1 TR001102NIA NIH HHS K23 AG049087NIA NIH HHS K24 AG035007NIA NIH HHS P01 AG036694NIA NIH HHS R01 AG046396NIA NIH HHS U01 AG024904NIA NIH HHS U19 AG010483NINDS NIH HHS U01 NS082157
Abstract
objectiveTo better understand cross-sectional relationships between CSF and PET measures of tau pathology, we compared regional and global measures of (18)F-T807 (AV-1451) PET to CSF protein levels of total tau (t-tau), phosphorylated tau (p-tau), and β-amyloid 1-42 (Aβ42).
methodsT-tau, p-tau, and Aβ42 levels were assessed using INNOTEST xMAP immunoassays. Linear regression was used to compare regional and global measures of (18)F-T807 standardized uptake value ratios (SUVR) to CSF protein levels using data from 31 cognitively unimpaired elderly participants in the Harvard Aging Brain study.
resultsAfter controlling for sex and age, total cortical (18)F-T807 binding was significantly correlated with p-tau (partial r = 0.48; p < 0.01) and at trend level with t-tau (partial r = 0.30; p = 0.12). Regional (18)F-T807 measures were more strongly correlated with CSF protein levels than the global measure, with both t-tau and p-tau significantly correlated with (18)F-T807 SUVR in entorhinal, parahippocampal, and inferior temporal cortical regions (partial r = 0.53-0.73). Peak correlations between CSF and PET measures of tau were similar to those between CSF and PET measures of amyloid burden. Finally, we observed significantly higher temporal T807 SUVR in individuals with high amyloid burden.
conclusionsThese data support the link between (18)F-T807 PET and CSF measures of tau pathology. In these cognitively normal individuals with (18)F-T807 binding largely restricted to the temporal lobe, (18)F-T807 SUVR in temporal regions appeared more reflective of CSF t-tau and p-tau than a total cortical measure.
Indexed as
AgedAged, 80 and overAmyloid beta-PeptidesApolipoprotein E4BrainCarbolinesCross-Sectional StudiesFemaleGeriatric AssessmentHumansMagnetic Resonance ImagingMaleMental Status SchedulePhosphorylationPositron-Emission Tomographytau Proteins7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleAmyloid beta-PeptidesApolipoprotein E4Carbolinestau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.